BioMarin Amicus Acquisition: $4.8 Billion All-Cash Deal Positions Rare Disease Leader for Accelerated Growth
BioMarin Pharmaceutical (BMRN) announced on December 19, 2025, that it has entered into a definitive agreement to acquire Amicus Therapeutics Inc. (NASDAQ: FOLD) in an all-cash transaction valued at approximately $4.8 billion, creating a formidable powerhouse in the rare disease […]










